Comparative Analysis of Adverse Event Profiles Among Seven Statins for Hypercholesterolemia Management Using the United States FDA Adverse Event Reporting System.
Level 4 - case-series / case-control
Retrospective pharmacovigilance analysis of spontaneous adverse event reports (FAERS)
PubMed 40291284 · doi:10.7759/cureus.81260
What was done
A retrospective pharmacovigilance study analyzed US FDA Adverse Event Reporting System (FAERS) reports from 2004 to 2024 to compare adverse event (AE) profiles among seven statins: atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, and pitavastatin. To reduce confounding, only reports with a documented indication of hypercholesterolemia were included. Adverse events were classified into 10 categories. The authors performed 21 pairwise comparisons using reporting odds ratios (ROR) and adjusted reporting odds ratios (aROR) controlling for patient baseline variables, applying a Bonferroni-corrected significance threshold of p < 0.0024.
What was found
The abstract does not report specific numerical values, point estimates, or confidence intervals for the effect sizes. With atorvastatin as the reference drug, five statins (simvastatin, rosuvastatin, pravastatin, fluvastatin, and pitavastatin) demonstrated statistically significant increased reporting (both ROR > 1 and aROR > 1) for gastrointestinal disorders. Conversely, five statins (simvastatin, rosuvastatin, pravastatin, lovastatin, and pitavastatin) showed significantly lower reporting (both ROR < 1 and aROR < 1) for metabolic disorders relative to atorvastatin. Overall comparisons across other reference statins showed heterogeneous, statin-specific AE distribution patterns across categories.
Why it matters
The study suggests that safety and tolerability signals differ across individual statins despite a shared mechanism of action, which may help clinicians tailor statin selection according to individual patient risk profiles.
Limits
The total sample size of reports analyzed is omitted from the abstract. Findings are derived from FAERS, a spontaneous reporting database vulnerable to reporting bias, underreporting, missing clinical details, and lack of a true exposed denominator, precluding incidence calculations or causal inference. Residual confounding from dose differences and co-medications cannot be ruled out.
Cited by
- supports There are currently seven distinct statin medications approved and in clinical existence.